UNLIMITED TURBO LONG - UNITED THERAPEUTICS Stock

Certificat

DE000PD4W3E2

Delayed Deutsche Boerse AG 12:05:15 2024-06-13 EDT
11.71 EUR +3.63% Intraday chart for UNLIMITED TURBO LONG - UNITED THERAPEUTICS
Current month+7.11%
1 month+14.95%
Date Price Change
24-06-13 11.71 +3.63%
24-06-12 11.3 +4.73%
24-06-11 10.79 0.00%
24-06-10 10.79 +0.65%
24-06-07 10.72 -0.28%

Delayed Quote Deutsche Boerse AG

Last update June 13, 2024 at 12:05 pm

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellCALL
Underlying UNITED THERAPEUTICS CORPORATION
IssuerLogo Issuer BNP Paribas BNP Paribas
WKN PD4W3E
ISINDE000PD4W3E2
Date issued 2022-04-14
Strike 160.8 $
Maturity Unlimited
Parity 10 : 1
Emission price 4.92
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 13.93
Lowest since issue 3.91

Company Profile

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Sector
-
More about the company

Ratings for United Therapeutics Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: United Therapeutics Corporation

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
281.9 USD
Average target price
295.9 USD
Spread / Average Target
+5.00%
Consensus